Endra Life Sciences Inc. · NASDAQ:NDRA
Endra Life Sciences — Investor Presentation (June 2020)
15 slides from Endra Life Sciences's investor presentation, Jun 1, 2020
Slide 1: Addressing the Need in Liver Disease (NAFLD-NASH) Diagnosis
Addressing the Need in Liver Disease (NAFLD-NASH) Diagnosis INVESTOR PRESENTATION JUNE 2020 ENDRA LIFE SCIENCES NASDAQ: NORA
Slide 2: Safe Harbor
Safe Harbor Certain statements made in this presentation are forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial positi
Slide 3: ENDRA Snapshot
ENDRA Snapshot GOAL: VISUALIZE HUMAN TISSUE LIKE MRI... AT 50X LOWER COST? & POINT OF PATIENT CARE eo © & ~20 employees Leadership, advisors, & Plug-and-play imaging platform with {*' clinical application: Liver disease partners from GE Healthcare, $18 billion opportunity to expand (NAFLD-NASH) affe
Slide 4: Focused on a Large and Rapidly Growing Market: NAFLD-NASH
Focused on a Large and Rapidly Growing Market: NAFLD- NASH TOTAL ANNUAL DIRECT MEDICAL COSTS IN U.S. FOR NAFLD: ~$103B? Burden f Liver Dens {* billion people have NAFLD-NASH.? Linked to obesity, diabetes, genetics, metabolic syndrome Non-Alcoholic Fatty Liver Disease (NAFLD): Build-up of fat in the
Slide 5: Measuring Liver Fat in NAFLD-NASH Patients
Measuring Liver Fat in NAFLD-NASH Patients CURRENTLY NO PRACTICAL, RIGOROUS TOOL FOR STAGING THE DISEASE HIGH ENDRA’s Goal: 5 An accessible, safe, hight —_ 2 < -value liver fat rs) measurement tool = wn ie) 4 : oO H < i Blood Medical : Test History Low Low ACCESS / AFFORDABILITY HIGH ENDRA LIFE SCIE
Slide 6: Total Addressable Market for NAFLD-NASH Fat Measurement Tool
Total Addressable Market for NAFLD-NASH Fat Measurement Tool $1 BILLION OPPORTUNITY ... WITH UPSIDE Estimated 2019 Number of Facilities! Global facilities (primarily radiology) currently doing abdominal- 20,000 Performing Abdominal-Liver Ultrasound Scans 77> liver ultrasound scans, who could potenti
Slide 7: Solution: Thermo Acoustic Enhanced UltraSound (TAEUS)
Solution: Thermo Acoustic Enhanced UltraSound (TAEUS’) RF SIGNALS QUANTITATE LIVER FAT FRACTION Y Secured ISO 13485 Certification Y Completed first human feasibility study (N=19) + Sensitivity 0.88 Specificity 0.82 AUROC 0.91 @ MRI-PDFF 6% steatosis Y Obtained CE Mark: European regulatory approval Y
Slide 8: TAEUS Platform Evolution
TAEUS™ Platform Evolution: MULTIPLE POTENTIAL CLINICAL APPLICATIONS & REVENUE STREAMS TO SCALE BUSINESS HARDWARE SOFTWARE DISPOSABLES LICENSING TAEUS accessory increasing utlity TAEUS SW applications added to TAEUS E.g. Applicator pads to enhance TAEUS — Build-in TAEUS as feature of new OEM of exist
Slide 9: ENDRA 2020 Milestones: Liver Application
ENDRA 2020 Milestones: Liver Application SECURE REGULATORY APPROVALS AND INSTALL FIRST COMMERCIAL SYSTEMS 1H ‘20 2H ‘20 Y Obtain CE Mark certification Announce additional EU & US evaluation sites Y Add hepatology influencer to ENDRA clinical advisory Execute controlled launch in EU with early adopte
Slide 10: ENDRA Partners
ENDRA Partners SUPPORTING TECHNICAL, CLINICAL & COMMERCIAL DEVELOPMENT OF TAEUS GE Healthcare Strategic partnership © Supports product development and introductions to GE ultrasound customers ¢ GEhas option to for | year sales exclusivity on TAEUS liver application, and other rights ener © UPMC Univ
Slide 11: Commercialization: Targeting High Value Clinical Segments
Commercialization: Targeting High Value Clinical Segments BUILDING AWARENESS, RELATIONSHIPS & BASE OF CLINICAL EVIDENCE IMAGING EXPERTS LIVER EXPERTS METABOLISM & i x LIFESTYLE EXPERTS ENDRA APPROACH Radiology Gastro-Hepatology since ‘18 100,000 global .. 45,000 global Social media, online - ' . \ E
Slide 12: Leadership
Leadership MANAGEMENT aby) ay Francois Michelon Michael Thornton Chairman & CEO clo 20° years in med-tech 15° years med-tech GE Healthcare, Smith & Nephew, Founder, Enhanced Biomet Vision Systems (sold to GE) INDEPENDENT DIRECTORS Sam Gambhir, MD, PhD Michael Harsh Chair of Radiology, Stanford Unive
Slide 13: ENDRA Investment Highlights
ENDRA Investment Highlights Targeting clear unmet need in liver disease (NAFLD-NASH), affecting 1B* people KEY STATISTICS (as ofMay 14, 2020) Large addressable market with no current practical tools; only expensive MRI or invasive liver biopsy Advent of first targeted NAFLD-NASH therapies increases
Slide 14: Contact Us
CONTACT US ENDRA LIFE SCIENCES A David Wells : Chief Financial Officer (734) 997-0464 Investors@endrainc.com NASDAQ: NORA
Slide 15: Sources & Assumptions
Sources & Assumptions PAGE3 1 SSOKENDRA device estimated price compared to $2.5N NR price 2 2020 aidressatie systems comprised of cart-based, non-prenatal utrasounds, a subset of estimated IN instaled giobal systems. based on GobaDate MedPoint, 20H report indicating 800.000 units growing at 4.5% CAG
ENDRA Life Sciences — Investor Presentation (June 2020) on 6ix